NANOG, SOX2, and OCT4 expression was evaluated by immunochemistry in 348 surgically-treated HNSCC, and correlated with clinicopathological parameters and patient outcomes. The gene discussed is NANOG; the disease is head and neck squamous cell carcinoma.